RENAL CELL CARCINOMA

This study is testing whether adding a new oral drug called ciforadenant to two existing immunotherapy drugs (ipilimumab and nivolumab) can better control advanced kidney cancer. It aims to see if this three-drug combination is safe and effective for adults who have not yet recei…

This study is testing the safety of two new drug combinations for people with advanced kidney cancer that cannot be removed by surgery. It compares a new immunotherapy drug (tobemstomig) plus a targeted therapy (axitinib) against the current standard treatment. The goal is to see…

This study is testing if taking the drug sunitinib before surgery helps control advanced kidney cancer that has spread. Fifty patients who are eligible for surgery to remove their primary kidney tumor will take sunitinib for four weeks, have surgery, and then continue the drug. R…

This study aimed to test a new gel called PuraBond, designed to quickly stop bleeding and help tissue heal after surgeons remove part of a kidney to treat cancer. The gel would have been tested in patients undergoing robotic surgery where standard methods to stop bleeding were no…

This study is testing whether adjusting medication doses based on tumor response can help control advanced kidney cancer. It combines two existing drugs (pembrolizumab and axitinib) in a new way for patients who haven't had previous treatment for their metastatic cancer. The tria…

This study compares two existing drugs, cabozantinib and sunitinib, for patients with advanced, rare types of kidney cancer that have spread. The goal is to see which drug is better at controlling the cancer's growth and which has fewer side effects. Participants are randomly ass…

This is the first human study of a new cancer drug called AB248, testing it alone or combined with an existing immunotherapy (pembrolizumab). The trial aims to find safe doses and see early signs of effectiveness in adults with advanced solid tumors that have spread or cannot be …

This is an early-stage study to find a safe dose of a new drug called HFB200603, given alone or with an existing immunotherapy (tislelizumab), for people with advanced cancers that have stopped responding to standard treatments. The trial will enroll about 83 adults with specific…

This study is testing whether a new medical device called the GPX Embolic Device is safe and effective for blocking blood vessels. Doctors use this procedure, called embolization, to cut off blood flow to vascular tumors and other problem areas in the body. The trial will follow …

This study is testing whether a new immunotherapy drug (BGB-A445) works better when combined with an existing one (tislelizumab) to treat advanced bladder, kidney, or skin cancers. It aims to see if the combination can shrink tumors and is safe for patients. The trial is for peop…

This study is comparing the effectiveness and safety of two immunotherapy drugs (nivolumab and ipilimumab) given together versus using just one of them (nivolumab alone). It is for adults with advanced kidney cancer that has spread and who have not yet received any treatment for …

This early-phase study is testing the safety of combining a new cancer vaccine with an existing immunotherapy drug (pembrolizumab) in patients with advanced solid tumors that have spread and stopped responding to standard treatments. The vaccine is designed to train the immune sy…

This study is testing whether combining three medications—cabozantinib, nivolumab, and ipilimumab—can safely slow the growth of advanced kidney cancer that has spread. The trial will enroll about 60 adults with specific types of non-clear cell kidney cancer that cannot be surgica…

This study is testing whether adding the drug palbociclib to belzutifan works better than belzutifan alone for advanced kidney cancer. It involves 60 patients whose cancer has worsened despite at least two prior treatments. The main goals are to find a safe dose for the combinati…

This early-stage trial is testing a new drug called INBRX-106, both by itself and combined with an existing immunotherapy (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see how …

This study is testing a new oral drug, ARRY-614, to see if it can make standard immunotherapy drugs (nivolumab and ipilimumab) work better for people with advanced cancers. The first part checks the safety and best dose. The second part will see how well the combinations work to …

This study is testing a new combination of immune-boosting drugs for people with advanced cancers whose disease has progressed after treatment with standard immunotherapies like pembrolizumab or nivolumab. It aims to see if adding a drug called NAI to other treatments can help sh…

This study is testing whether adding a personalized mRNA vaccine (V940) to a standard immunotherapy drug (pembrolizumab) is better at preventing kidney cancer from coming back after surgery than the immunotherapy drug alone. It involves about 272 people who have had surgery for i…

This study is collecting real-world data on a freezing treatment (cryotherapy) for kidney cancer. It follows 120 patients for up to 5 years to see how well the treatment destroys tumors and prevents them from coming back. The main goals are to confirm the procedure's safety and m…

This early-stage study is testing the safety and best doses of a combination of cancer drugs for people with advanced cancers of the urinary system (like bladder and kidney cancer) that have spread. The trial combines a pill (cabozantinib) that aims to block tumor growth with one…

This study is testing if a short, high-dose radiation treatment given before surgery is safe and effective for people with kidney cancer that has grown into a major vein (the IVC). The goal is to see if this approach helps control the cancer, reduces the risk of it spreading duri…

This study followed 86 patients with kidney cancer that had spread to other body parts after they had surgery to remove those secondary tumors. The goal was to see if this surgical approach helps keep the cancer from progressing or returning. Researchers tracked patients' health …

This is an early-stage study to find a safe dose of a new immunotherapy drug called HFB200301. It is being tested alone and in combination with an existing drug (tislelizumab) in adults with advanced solid tumors who have already tried other treatments. The main goal is to see ho…

This study is testing a drug called entrectinib for people with advanced solid tumors that have specific genetic changes (NTRK, ROS1, or ALK gene rearrangements). It's a 'basket trial,' meaning it groups patients by their tumor's genetic type rather than where the cancer started …

This large, late-stage trial tested whether two new drug combinations work better than the current standard treatment for advanced kidney cancer. It enrolled over 1000 patients who had not yet received treatment for their advanced disease. The goal was to see if the combinations …

This study is testing three different combinations of immunotherapy drugs given to patients before surgery for intermediate-to-high-risk kidney cancer. The goal is to see which drug combination best shrinks the tumor and reduces the chance of the cancer coming back after surgery.…

This study is testing whether a pill called cabozantinib can help control rare cancers that have come back or stopped responding to other treatments in children and young adults. It includes patients with sarcomas, Wilms tumor, and other rare tumors. The drug aims to slow or stop…

This study is testing whether combining two existing drugs, nivolumab and axitinib, is safe and effective for treating advanced kidney cancer. It will involve about 98 patients, including those who have had prior treatment and those who have not. The first part finds the safest d…

This is a first-in-human study testing a new type of cancer treatment called P-MUC1C-ALLO1 in adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find a safe dose and see how well the body tolerates this 'off-the-shelf' CAR-T …

This study is testing whether a targeted radiation drug called 177Lu-PSMA-617 can help control advanced kidney cancer that has spread. The treatment works by seeking out cancer cells and delivering radiation directly to them. The trial involves about 24 patients whose cancer has …

This early-stage study is testing a new three-drug combination for people with advanced melanoma or kidney cancer. The main goal is to find a safe and tolerable dose of the new drug, APX005M, when given with two existing immunotherapy drugs. Researchers will enroll about 26 patie…

This early-stage study is testing the safety and initial effects of a new drug, belzutifan, given alone and in combination with other cancer drugs (lenvatinib and pembrolizumab) for people in China with advanced kidney cancer. It will enroll 45 participants to see how their bodie…

This study is testing if taking the drug cabozantinib for 12 weeks before surgery can shrink advanced kidney tumors that have not spread. The goal is to see if this pre-surgery treatment helps control the cancer and makes surgery more effective. Researchers will measure tumor shr…

This early-stage trial is testing the safety and finding the right dose of a two-drug combination (naptumomab estafenatox and durvalumab) for people with advanced or metastatic solid tumors. It will enroll about 120 adults with one of many eligible cancer types, including breast,…

This study is testing if a fecal transplant (transferring healthy gut bacteria from a donor) can help patients with advanced kidney cancer better tolerate a powerful two-drug immunotherapy combination. The goal is to reduce severe side effects so patients can stay on their cancer…

This large, late-stage trial is comparing a three-drug combination to the current standard two-drug treatment for people with advanced kidney cancer who haven't had prior therapy. The study aims to see if adding a third drug helps patients live longer without their cancer getting…

This study is testing a new tracking system that works like a mini-GPS inside a needle. It aims to help doctors more accurately guide needles to hard-to-find tumors during biopsy or ablation procedures, using a weak magnetic field. The research will see if this 'smart needle' can…

This study aims to understand what types of bacteria and fungi are present in the urine and kidney tissues of people with calcium oxalate kidney stones or kidney cancer, compared to healthy people. Researchers will collect samples from 90 participants during their standard medica…

This study is testing whether a special type of CT scan can help doctors see if cancer drugs are working sooner. The scan measures blood flow to kidney cancer tumors. About 120 patients with advanced kidney cancer will get these scans before and after starting drug treatment to s…

This early-stage study is testing a tiny, implantable device to see if it can safely help doctors figure out which cancer drugs work best for an individual's kidney tumor. The device, placed into a tumor before surgery, releases tiny amounts of 19 different drugs already used to …

This study looks back at medical records to understand how well immunotherapy cancer drugs work for American Indian patients compared to White patients. Researchers will analyze survival times, side effects, and cancer-related deaths in 72 patients who were treated between 2015 a…

This study is creating a registry to collect medical information, tissue samples, and images from people with a rare type of kidney cancer called TFE Renal Cell Carcinoma. The goal is to gather data to help scientists understand the biology of this cancer better. This knowledge i…